S
3.38
0.15 (4.64%)
| Previous Close | 3.23 |
| Open | 3.23 |
| Volume | 52,077 |
| Avg. Volume (3M) | 60,385 |
| Market Cap | 130,450,400 |
| Price / Sales | 1.61 |
| Price / Book | 1.65 |
| 52 Weeks Range | |
| Earnings Date | 13 Nov 2025 |
| Operating Margin (TTM) | -24,342.11% |
| Diluted EPS (TTM) | -0.940 |
| Quarterly Revenue Growth (YOY) | -41.50% |
| Total Debt/Equity (MRQ) | 0.60% |
| Current Ratio (MRQ) | 2.02 |
| Operating Cash Flow (TTM) | -26.74 M |
| Levered Free Cash Flow (TTM) | -16.66 M |
| Return on Assets (TTM) | -22.10% |
| Return on Equity (TTM) | -41.36% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Mixed |
| Medical Devices (Global) | Mixed | Mixed | |
| Stock | Sera Prognostics, Inc. | Mixed | Mixed |
AIStockmoo Score
-0.1
| Analyst Consensus | NA |
| Insider Activity | -5.0 |
| Price Volatility | -2.0 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | 5.0 |
| Average | -0.13 |
|
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Value |
| % Held by Insiders | 11.53% |
| % Held by Institutions | 69.95% |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| AERTS AUSTIN | - | 3.24 | -6,105 | -19,030 |
| BONIFACE JOHN J. | - | 3.40 | -1,332 | -4,529 |
| HARRISON ROBERT GARDNER | - | 3.15 | -2,616 | -7,894 |
| JACKSON BENJAMIN | - | 3.40 | -892 | -3,033 |
| KEARNEY PAUL | - | 3.15 | -33,416 | -97,513 |
| LAWRENCE SANDRA AJ | - | 3.05 | -1,560 | -4,758 |
| LINDGARDT ZHENYA | - | 3.24 | -32,370 | -100,747 |
| MIRZA MANSOOR RAZA | - | 3.08 | -292 | -899 |
| Aggregate Net Quantity | -78,583 | |||
| Aggregate Net Value ($) | -238,404 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 3.21 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| AERTS AUSTIN | Officer | 10 Dec 2025 | Sell (-) | 873 | 3.40 | 2,968 |
| BONIFACE JOHN J. | Officer | 10 Dec 2025 | Sell (-) | 1,332 | 3.40 | 4,529 |
| HARRISON ROBERT GARDNER | Officer | 10 Dec 2025 | Sell (-) | 616 | 3.40 | 2,094 |
| JACKSON BENJAMIN | Officer | 10 Dec 2025 | Sell (-) | 892 | 3.40 | 3,033 |
| KEARNEY PAUL | Officer | 10 Dec 2025 | Sell (-) | 1,213 | 3.40 | 4,124 |
| LINDGARDT ZHENYA | Officer | 10 Dec 2025 | Sell (-) | 4,155 | 3.40 | 14,127 |
| AERTS AUSTIN | Officer | 09 Dec 2025 | Sell (-) | 5,232 | 3.07 | 16,062 |
| LINDGARDT ZHENYA | Officer | 09 Dec 2025 | Sell (-) | 28,215 | 3.07 | 86,620 |
| LAWRENCE SANDRA AJ | Director | 08 Dec 2025 | Automatic sell (-) | 1,560 | 3.05 | 4,758 |
| MIRZA MANSOOR RAZA | Director | 05 Dec 2025 | Sell (-) | 292 | 3.08 | 899 |
| KEARNEY PAUL | Officer | 02 Dec 2025 | Sell (-) | 32,203 | 2.90 | 93,389 |
| KEARNEY PAUL | Officer | 02 Dec 2025 | Option execute | 32,203 | - | - |
| HARRISON ROBERT GARDNER | Officer | 02 Dec 2025 | Automatic sell (-) | 2,000 | 2.90 | 5,800 |
| Show more | ||||||
| Date | Type | Details |
|---|---|---|
| 24 Nov 2025 | Announcement | Sera Announces Publication Acceptance for PRIME Study |
| 13 Nov 2025 | Announcement | SERA PROGNOSTICS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS |
| 30 Oct 2025 | Announcement | SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF THIRD QUARTER FISCAL YEAR 2025 FINANCIAL RESULTS ON NOVEMBER 13, 2025 |
| 01 Oct 2025 | Announcement | Sera Prognostics Names Dr. Tiffany Inglis Chief Medical Officer |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |